Macrophages are specialist cells that have developed an innate capacity to recognize subtle differences in the structure of cell surface epressed identification tages, so called molecular patters. They arrive later to a site of infection as compared to neutrophils. Unlike neutrophils (PMNs), macrophages are also longer lived and they are present in tissues as well as in blood. Macrophages patrol the body’s tissues, searching for signs of infection. When they detect a foreign protein, they set off the inflammatory response. In particular, they engulf and destroy the invader bearing that protein and secrete a suite of cytokines, some of which raise an alarm that recruits other cells to the site of infection and puts the immune system on alert. 

What Do Macrophages Do?

Anti-Bacteria Activity: Macrophages are in a resting state but can be activated by bacterial products like LPS as well as cytokines secreted by activated . like IFN-y which is secreted by TH1 cells. Activated macrophages have increased phagocytic and microbicidal activity (such as oxygen dependent mechanisms that catalyzes the reduction of oxygen to superoxide anion (O2-) which generates other oxidizing agents harmful to bacterial like hydrogen peroxide).  A group of antimicrobial and cytotoxic peptides known as defensins are also present in activated macrophages.

Macrophages play important role in host defense and inflammation. First, macrophages can act as effector cells in killing phagocytosed and extracellular microbes and tumor cells by producing reactive oxygen intermediates, nitric oxide (NO), and lysosomal enzymes.

Mqs endocytose particles or soluble glycoconjugates taht are bound by the mannose receptor, a C-type lectin with broad carbohydrate specificty, Mqs also have a receptor for LPS.

Cytokines secreted by Macrophages: Production of cytokines by macrophages is considered one of the important immunoregulatory function sof macrophages. Macrophages regulate the immune response of T cells through producing important cytokines such as IL-12 and IL-10. These two cytokines can enhance Th1 or Th2 cell differentiation, respectively, result in enhancing or suppressing of cell-mediated immunity. Macrophages are also progenitors of inflammatory cytokines, such as TNF-alpha, IL-1 and Il-6.

Tissue macrophages respond to the perception of microorganisms with phagocytosis of the pathogens and the production of cytokines. Among these TNFa, IL-12 p70 and IL18 induce the secretion of IFNy from NK cells. IFNy then converts macrophages harboring pathogens to a a microbicidal state, in which bactericidal agents such as NO and reactive oxygen intermediates are porduced to kill the bacteria.

Phagocytosed antigen is digested within the endocytic processing pathway into peptides that associate with class II MHC molecules which then move to the macrophage membrane. Activation of macrophages induces increased expression of both  class II MHC molecules and the co-stimulatory B7 family of membrane molecules which allows macrophages to function more effectively as antigen presenting cells. Macrophages also secrete a number of proteins central to development of immune responses such as interleukin 1 which acts on  and provides a costimulatory signal required for activation following antigen recognition. Thus, macrophages and  facilitate each other’s activation during the immune response.

The macrophage membrane has receptors for certain classes of antibody and thus will bind better to antigen which is complexed with antibody. Thus antibody functions as an opsonin, a molecule that binds to both antigen and macrophage and enhances phagocytosis. Opsonization is the process by which particular antigens are rendered more susceptible to phagocytosis. 

Macophages express substantial levels of the F4/880 antigen, and for the most part express little or no NHC class II.

Specialized Types of Macrophages in the Body:

Kupffer cells (KCs): reside within the lumen of the liver sinusoids and form the largest population of macropahges in the body. Although KCs have markers in common with other tissue resident macrophages, they perform specialized functions geared towards efficient clearance of gut dervied bacterial, microbial deris, bacterial endotoxins, immune complexes and dead cells present in portal vein blood draining from the microvascular system of the digestive tract. Efficient binding of pathogens to the KC surface is a crucial step in the first line immune defense against pathogens. A central role for KCs in the rapid clearance of pathogens from the circulation is illustrated by the significanlty increased mortality in mice depleted of KCs.

Common Cell Types: Polypeptides for use in pharmaceutical applications are mainly produced in mammalian cells such as CHO cells, NSO cells, Sp2/0 cells, COS cells, HEK cells, BHK cells, PER.C6® cells and the like (WO 2009/010269). Recombinant therapeutic proteins are commonly produced in several mammalian host cell lines including murine myeloma NSO and Chinese Hamster Ovary (CHO) cells (WO 2008/091740) and (Van Reis, “Bioprocess membrane technology, Science 297 (2007) 16-50) . 

Cell Growth mediums: 

A mammalian cell culture begins with a mammalian tissue. The tissue is dissociated either mechanically or enzymatically or by a combination of the two to yield a mixture of single cells and small clups of cells. The mixture is inoculated into an appropriate liquid growth medium that ordinarly includes salts, glucose, certain amino acids, vitamin and blood serum (about 20% of the medium). The serum is included as a means of providng components that have not all been identified but are needed if the cells are to live and grow.

Fetal calf serum (FCS) is considered the best available serum for this purpose.

Cohn Fractions:  MacLeod (EP0440509 A2) discloses growth medium components which when added to cell growth media can be used as a replacement for FCS. The medium is free from active virsues and essentially immunogloublin free. MacLeod also describes a process for producing the medium using Cohn fractions, adjusting the pH to 7-8, adding polyethylene glycol and then diluting the resultant liquid with water or a suitable buffered saline. Subsequently the resultant solution is pasteurised by heating.

Mouse bone marrow/GM-CSF:

When suspensions of mouse bone marrow are cultured in the presence of GM-CSF, 3 types of myeloid cells expand in numbers (a) neutrophils predominate but do not adhere to the culture surface. (b) Macrophages are firmly adherent to the culture vessel. (c) dendritic cells arise from cellular aggregates that are attached to the marrow stroma. The aggregates become covered with sheet-like cell processes and eventually release typical single dendritic cells.

Production of Antibodies in cell culture (see antibody production)

 

Protocols Involving Dendritic Cells:

Infecting Dendritic cells with LP

In this experiment, we will infect dendritic cells which have been obtained from the bone marrow of mice. See on how to obtain such dendritic cells.

Prepare 5% RPMI without Antibiotic 

Collect Your DC cells: (They are in the medium)

reagents: –prepare 10% RPMI without Antibiotic  –pour some PBS into 50 ml tube and let warm up *in incubator for 10 minutes if want; needs to be room temp)

1) At this point your DCs have been in culture for 6-10 days. 

2) Your cells will be a mixture of macrophages which adhere to the plate and dendritic cells (most of which do not adhere). Using pipette, siphone off the liquid being careful not to scrape and stire up the macrophages which are adhered to the place. Place liquid into 50 ml tube. 

(3) Add about 1 ml (room temp) PBS to each well plate in order to wash the rest of DC. Room temp PBS will not lift the macrophages. Place liquid into your 50 ml tubes.

(4) spin at 10 C at 1100 RPM for 10 min.

(5) Remove supernatent

(6) resuspend cells and transfer to tube using 10 ml medium (use 10% RPMI but without antibiotic since antibiotic will inhibit the infectivity of Lp)

(7) count the cells as below. (always keep cells on ice while doing anything!)

 

Prepare LP:

 

reagents: –blank cuvette, sample cuvette, transfer pipette, 2×2 square of parafilm –also turn on machine so warms up

 

(5) Put saline (about 5 ml) into 15 ml tube. take a   [this is a tube which has been taken from -80, streaks out onto agar and incubated for 48 hours) which is on special agar (BCYE). Use swab end to collect and put into your tube. Repeat with cotton swab if necessary. You should just barely see letter in back of tube. (if you do not see you can add more saline)

 

(6) take 1 ml of LP-solution and transfer to disposable cuvette. (place parafilm around cuvette!)

 

(7) take OD reading. get blank in drawer. put blank in. Change wave lenght to 620. change parameter so can print out. Convert reading using graph into number CFU. (write this on the tube!)

 

<Turn on> (takes 5 min) 1st place blank in. <1><enter>”change parameters”  change the second alpha to “620” (the first stays the same at “800) <Y> autozero <start> (need to be at 0). Place sample <start> again (your reading should be close to 1 (e.g., .834 converts to 21×108 so write on tube 2.1 x 109) hit return and turn machine off

 

(8) ) take your DC cells out of centrifuge from (4) above and pour off supernatent into sink. Transfer pellets into 15 ml tube having about 10 ml RPMI (if not expecting a lot of cells can use 5 ml). (so you can pipette a 3 ml RPMI volume up and down in one 50 ml tube and do the same for the others to get that 10 ml volume. You will need to know this final volume for calculations below)

 

Count your DC cells:

 

(9) take 50 ul from your tube and add to 50 ul tryptan blue (you can do this in a well plate) Look under microscope low magnification 1st for grid. count 5 squares. (corners and middle)

 

# cell counted X 2 X 5 X 104 (for the cuvette) x 10 =  your total # cells per ml

 

[Let say your total number is 20 x 10per ml. We want a final concentration of 1 X 106 per ml. What volume should we resuspend our cells in to get this final concentration?

 

20 x 10/ X = 1 X 106 / 1 ml

 

 

x= 20 ml.   So if our starting concentration was 10 ml we would need to add another 10 ml to get this final concentration. (use larger 50 ml tube to make this appropriate volume)

(10) Now your are ready to Transfect your cells.

Transfecting Cells:

(1) The infection ratio is 10:1. So figure out how much of your Lp you should use to infect your cells. Suppose you have 4 million cells. You would use 14 ul of LP. So spin your cells down (want to infect in about 1 ml), add 14 ul of LP and incubate at 37 C for 30 min.

Ex. you have 4 million cells and 2.8 x 109 cell/ml bacteria. How much LP should you add? 

2.8 X 109 cells/ml (X) = 4.0 X 10X=4.0 X 107 / 2.8 X 109        =1.4 X 10-2 = .014 ml = 14 ul of LP

Ex. From your OD reading you determine you have 2.3 x 10e9 cells/ml Lp. You have counted 5 million cells/ml of DCs. You u want an infection fatio DC:Lp of 1:10 how much Lp should you add?

2.3 X 109 cells/ml (X) = 5.0 X 10X=21.7 ul

Remove Excess LP (wash the cells)

(1) add Hanks solution (HBSS) to the tubes (fill up the tubes with hanks). Always pour Hanks from the large stock flask into a smaller flask and from there into your tubes. Centrifuge for 10 min

(2) remove supernatent (make sure this goes into bleach since it is infected and let it sit for an hour!)

(3) repeat by filing tube with hanks, spin, and then removing supernatent into bleach

Resuspend pellet in appropriate amounts medium 

(1) If, for example, you had 4 million cells in the pellet, you might  add 4 ml media to get 1 million cells/ml. This will all depend on your experiment.

 

Measuring Cell Concentrations

Question (Concentrations: cells): You want to split cells into a new flask so that the flask with have a 50 ml volume and final cell concentration of 4 * 10. Your flask with cells has a volume of 50ml and a concentration of 25 * 104. What the volume that should be take out of this flask to end up with your desired final concentration?

(CI V= C2 V2)     (25 * 104V= (50 ml) (4 * 105)

V80 ml                    This volume is clearly more than what is in the flask. So we will instead have to spin the cells down and add media instead. What then should be the volume of the second flask to get the desired final concentration?

(CI V= C2 V2)     (25 * 10450 ml= (V2) (4 * 105)

V31.25 ml      So spin down the flask having 50 ml and then resuspend the cells in about 32 ml.

Question (Concentrations: cells): You want 15 ml of cells at a concentration of 50,000 cells/50 ul. After doing a cell viability count, you figure that you have 280K cells/ml in a flask which has the cells suspended in about 75 ml. What volume would you need to take out of that flask to get your desired concentration?

(CI V= C2 V2)     (280Kcells/ml) V= (15 ml) (50 K cells/0.05 ml)

V= 53.5 ml

Question (Concentrations: cells): After counting cells, you find that you should have 10 million in the pellet that you spun down (in this example, you came up with the # by mutiplying #cells X 2 (dilution factor) X 104 (volume of hemacytometer) X #ml (cell suspension). You want a concentration of 1 X 106. What volume should you resuspend your cells?

10ml

Question (Concentrations: cells): You have a [cells] or 1 X 106 and you would like a final [cell] of 2 X 105. What volume should you take from the 1 X 106 and place into your plate well for a final volume of 1 ml.

CI V= C2 V2)     (1 x 10cells/ml V= (1 ml) (2 x 105)

V10.2 ml or 200 ul    You should thus add 200 ul (this amount can never change!) to your 1 ml volume. So you might add 200 ul of cells + 800 ul media (this amount can change to make room for other chemicals).

Question (Concentrations: cells): You have a [cells] or 8 X 106 cells/ml and you would like a final [cell] of 1 X 106. From outlining your experiment, you determine that you need to use 13 wells in a 24 well plate (to do everything you want to accomplish). Is it possible to conduct your experiment at this concentration?

Yes. But you can not use 1 ml of you cells (brought up in 8 ml) because you will not have enough cells to distribute this way. What you must use is a smaller volume. If you use 0.5 ml instead of 1ml per well you can still keep a [final] of 1 X 106 . This would in fact allow you to use up to 16 wells. 

So now what volume should you take out of your 1 ml of cells to get this correct concentration?

CI V= C2 V2 (1 x 10cells/ml V(1 x 106)(0.5 ml)

V162.5 ul (this can not change!)  (Add this to your LPS + MDP up to a total volume of 0.5 ml)

Question (Concentrations: dendritic cells & LP infection): You determine that you have 16 million dendritic cells/ml and after your OD reading that you have 2.9 X 109 bacterial cells/ml. You would like to infect your dendritic cells with the bacteria at a ratio of 10:1. What volume of LP should we take to get a 10:1 infection?

One way to do this is to multiply the dendritic cells by a factor of 10 and then divide by the # bacterial cells. So

16 X 10dendritic cells/ ml / 2.9 X 10bacterial cells/ml 

= 5.5 x 10-2 ml  or 0.055ml or 55 ml

Question (Concentration in multi-well plates): After counting cells, you find that you have 8 million cells suspended in 5 ml. You want a concentration of 1 million per 200 ul. What should you do?

CI V= C2 V2 (8 x 10cells/ml V(1 x 106)(0.2 ml)

V1= 125 ul 

Question (Concentration in multi-well plates): Suppose in question above that you want to set up a dilution of the cells much like an ELISA. you want to start your highest concentration of cells at 4 million.

4 million is 4x 25  so you would add 100 ul of your stock    to 100 ul media

2 million, add 50 ul        to 150 ul media

1 million, add your 25 ul    to 175 ul media

.5 million 12.5 ul    to 187.5 ul media

.25 million 6.25 ul    to 193.75 ul media

.125 million   3.125 ul to 196.875 ul media

Unthawing Cells:

(1) Obtain 2 50 ml tubes; place 10% C RPMI media in to one tube as working stock

(2) before cells are completely thawed, use 2 ml pipette to suck up cells (slowly mix them up and down a couple of times) and then transfer to empty 50 ml tube (let cells slide down the side of tube slowly as you rotate the tube)

(3) Using 2 ml pipette, transfer slowly 2 ml of RPMI media from working stock into tube with cells (do this slowly or cells will burst!). Repeat 4 more times until you have 10 ml total volume.

(4) Using 25 ml pipette transfer more media from working stock to tube with cells for final volume 50 ml

(5) spin 15 min at 1100 RPM (select RPMx1000) (can use big centrifuge outside room)

(6) aspirate with vacuum tube supernatent

(7) transfer 8 ml new media into tube (resuspend pellet by pipetting up and down)

(8) transfer contents of tube to small flask

Changing Media:

Molt-4 cells should be changed every 2-3 days. They grow quicker. maximum [cell] is 2×106 or they will die

(1) transfer cells in flask to tube and spin down

(2) remove supernatent

(3) Wash cells by adding about 50 ml hanks (HBSS) and resuspend pellet (you can add say 5 ml first and then take a 50 ul sample to count cells while spinning cells down)

(4) spin

(5) remove supernatent

(6) resuspend cells in 10 ml of 10% RPMI

Cell Mediums

RPMI + 1X P/S + 1X L-glu without serum (RO)  take the RPMI and dilute 1:100 with streptamycin and glutamine

Thawing Cells

Reagents: RPMI media (Roswell Park Memorial Institute) (Cellgro makes this). This is a special media for mammalian cells which have necessary vitaminnes, syrum and growth factors. 

(1) Look in log book (ex. “rack 10 box 2”) for location of cells (ex. MT-2 cells which are a cell line that express CD4+ receptor on their surface and are very susceptible to HIV infection). Mammalian cells will ideally be stored at 186 c whereas bacterial cells lines are typically stored at -70 or -80. Mammalian cells are frozen in presence of a 10% DMSO (dimethy sulfoxide). This means that mammalian cells will need to be stored in nitrogen machine. Take 2 cell tubes out. If you are not going to be working with the cells right away, put them at -80.

(2) Transfer cell tubes to ice bucket and then quickly thaw cell tubes in 37 c water bath. Do not overthaw since the presence of the DMSO can kill the cells!  You want to thaw just to the point the cells have thawed. 

(3) transfer cells using (2 ml pipette) into conical sterile tube (spray the tube and cap with 70% ETOH to help with sterility) which has 50 ml of RPMI media. 

(4) label the tube appropriately. (ex. MT-2, LN98074 F 1/19/99 T 6/16/03 JL 6/16/03)

Counting Cells

1) Look at the cells under a microscope. They will be clumped together.

2) Take a portion (~5 ml) from the flask of cells and transfer to sterile tube. Using the pipette, mix and break the cells by pipetting up and down about 10 times in the conical tube. This should be done under the hood.

3) Clean off with 70%ETOH a hemacytometer slide and cover slip with klenex. Transfer about 50 ul of the cells into a pipette from the conical tube and add 50 ul of Trypan Blue (can be purchased from Sigma) so that you end up with a 1:1 dilution.. Release the cells slowly into the groove of the hemacytometer so as to fill up the groove.

4) using a counter, count the number of live cells (they will have a shine about them) and dead cells (they will be stained by the trypan blue) in the 4×4 grid of the slide. The total volume of the grid is 0.1 ul. The total viability of cells can be determined by taking # of live cells/total # of cells * 100. For example, if you count 18 live cells out of a total of 34, this would be 18/34 * 100 = ~53 viability. In general, you want the viability up above 80%.

Question: 0.1 ul times what is equal to 1ml?

Answer: 0.1 ul x 1ml/1000ul = 0.0001 ml   So 0.0001 ml would need to be multiplied by 104 or 10, 000 to get 1 ml. This means that the total cells which we count in 0.1 ul under the microscope would have to be multiplied by 10,000 to get the total # of cells in ml of solution. So if you count 18 live cells, this means that you have 180K cells/ml. But since your are diluting in Trypan Blue at 1:1 you need to multiple this number by 2. So you would actually have 180K X 2.

Subcloning Cells

1) Cells will eventually use up their media and should be transferred to new media to maintain viability. One way to know when it is time to transfer the cells into new media is when the media becomes turbid (slight yellow color). So take a new flask and add about 35 ml of new media. To the old flash, add about 25 ml of media to provide those cells with new media. Label the flasks appropriately. Ex. MT-2, LN90741 F: 1/19/99 T 6/17/03 split 1:1 6/17/03.

Enriching Cells

(1) Count the total # of cells that you want to enrich. (ex. if you counted 24 lives cells above, you would multiply that by 10K and by 2 (for dilution factor) to get 480,000 cells/ml. Suppose your flask volume is 80ml you would multiply by 80 to get 38,400,000 cells total. Suppose you do this for a 2nd flask and get 59,200,00 cells total for 80ml in that flask. So you would add the total cells from both flasks to get 97,600,000 cells. We will want to have a final concentration of 1 * 10cells/2ml.

97,600,000cells/(x)ml = 1 * 10cells/2ml

x=1.952     So we are going to need to resuspend our cells in about 2 ml

(2) Prepare RPMI-5. (so if you have 20% you could add 10 ml R-20 and 40 ml R-0)

(3) Distribute cells into 50 ml tubes (yellow cap). So we could use 4 tubes with 40 ml each. 

(4) centrifuge 15 min, 800 RCF (or ~2160 RPM) (Accel=fast) (brake=slow)

(5) decant and resuspend pellet with 1 ml of solution(2) then transfer this volume to 2nd tube, and so forth until last tube where you bring the volume up to 2ml with solution(2) [cell concentration could be off so can also bring volume up to 2 ml with solution(2)]

(6) Add an equal volume of Ficol-Paque using glass pipette. Slowly release the Fico-Paque at the bottom of the tube being careful not to dispense any while moving the tube down or out. (create a balance tube having and equal volume of Ficol and RPIM-5]

(7) centrifuge again

(8) Using glass pipette suck out the fluffy layer in tube and transfer to new tube. Add  5 ml RPMI-5. 

(9) Centrifuge 10 min at 1080 RPM

(10) pour off supernatent and resuspend pellet with 10 ml of RPMI-5 

(11) resuspend pellet in 10 ml RPI-5. Check cell viability 1:5 by taking 10 mul of cells to 40 ul trypton blue.

(12) Divide cells in tube into flasks with desired volume (ex. 5 ml RPMI R-20 + 35 ml R-10. ex. 50 ml R-10)

Freezing Cells

Suppose that after counting cells (above) you count 53 live cells and 0 dead. So you would have 10,000 * 53 = 530,000 cells per 1 ml. You would actually have twice this amount or 1,060,000 cells/ ml in the flask since we diluted 1:1 with tryptan blue. 

Question: We want to take out 20 ml of our cells and resuspend those cells after centrifusion in what volume if we  want final [cell] to be 2 * 10cells/ml? 

1,060,000cells/ml * 20 ml * = 21,200,000 cells total

21,200,000 cells/x ml = 2,000,000 cells/ 1 ml

21,200,000 / 2,000,000 = x

10.6 ml = x

(1) Obtain and label specialized cell tubes. 

(2) we want to get tubes cold to enhance freezing so place them at -20.

(3) prepare freezing media. We want a 20 ml total volume freezing media (DMSO which is dimethly sulfoxide)  . So get conical tube (yellow cap) and add 

–18 ml of FBS (since we 90% FBS (20 * .90 = 18) +

–2ml DMSA (since we want 10% DMSO)

Mix tubes by inverting. Label (ex. “FM 90% FBS + 10% DMSA JL”) and place at -20c

(4) Obtain the flask with cells that contains 100% viability and add 20 ml to a conical tube.

(5) centrifuge tube at 1100 RMS for 10 min (make sure tubes are balanced and swinging buckets in tact)

(6) pour off liquid (cells will be at bottom)

(7) Transfer freezing media (3) above to tube (6). Pipette solution up slowly with 25 ml pipette to dissolve the cells. Use 5 ml pipette to transfer 1.3 ml into 14 vials (so will be using 18.2 ml total). 

(8) Place cell tubes into freezing container which has isopropyl alcohol poured into the bottom. Place this container at -70 for 4 hours (we want to freeze cells slowly which is the exact opposite from thawing). Label the 14 tubes “B16H78 2 * 106/28/03 JL”.

Companies: BioLife Solutions

For thawing cells, conventional practice is to warm the cells quickly in a warm water bath (e.g., 37 C) to just about the point to which the last bit of ice is about to melt and then to dilute the cells slowly into growth media. If the sample is allowed to get to warm the cells may start to metabolize, and be poisoned by the DMSO (dimethyl sulfoxide) that is used in the feezing prcoess. (Schryver, US Patent Application 15,602,711 published as US 2017/0257908 and US 10,917,941, which is a continuation of US Application 14.712,120 published as US 10,555,374)

Thawing Devices and Methods:

Pluristem LTD (CA 2883826) discloses a system for heating a biological material which includes a processor configured to receive an input associated with a target temperature and transmit a signal to controllably move a heating deice relative to the base for a time period, wherein the time period is detemriend based on the target emperature and content volumne. A method for thawing the frozen biological material includes the steps of controllably moving the heating device for a specific time period, wherein the time period is determiend based on the target emperature, the vial content material and the content volumne. Initially, a thawing cycle may active only after heating device has reached an initial temperature. This may reduce the affect of room and/or device temperature on the thawing procedure.

Thawing Protocols for Specific types of Cells: 

Thawing Melanoma cells:

Preparing Media (Dulbeo’s Modification Eagles Medium “DMEM”  ): 

(1) spray under hood with ETOH

(2) Add 50 ml of FBS to our bottel of DMEM. (We have a 500 ml volume and need to use 10% FBS so we will use 50 ml FBS.)

(3) Add 5ml of antibiotic solution (P/S/A “penicillin, streptomycin “antimicotic ) and 5 ml of L-glutamine (since we want a 1:100 dilution)

(4) invert the jugs a couple of times and store at 4c

(5) label “DMEM 10 + P/S/A JL date”

Thawing:

(1) obtain large conical tube (yellow cap) and transfer 30 ml of the media above. Use sterile conditions under the hood.

(2) get cells out from liquid N2 (ex. rack 10, Box 6, B-16; keep rack right on top of machine)

(3) thaw cells quickly in water bath and transfer with 2 ml pipette just as soon as cells have thawed.

(4) mix tube by inverting and then use 25 ml pipette to add the cells in the tube to sterile flask which has been labelled (ex. “B1678H1 F:2/27/94 T: 6/23/03 JLR”)

(5) observe cells under microscope in flask to access survivability  (“alive cells will adhere to bottom of flask and become dendritic. floating cells will be dead by tommorroo)

(6) grow these cells at 37.5 with falsk in horizontal position

US Patent Pub # 20040109851; Use of immature dendritic cells to selence antigen specific cd8cell function 

Immature DCs: Another way to generate suppressor T cells in vitro involves the stimulation of naive T cells with iDCs. Repetive stimulation of naive cord-blood T cells with allogeneic iDCs has reportedly generated a population of poorly growing T cells that primarily produce IL-10. Although these cells produced IL-10, their suppressor phenotype resembled that of CD25+ T cells, as it was contact dependent, antigen non-specific and APC independent. Furthermore, suppression could be overcome partially by the addition of IL-2. These cells differ from  in that IL-10 is not required for their generation because iDCs do not produce IL-10. The precursors of these suppressor cells in cord blood do not express CD25 so it is unlikley that they are derived form a CD25+ T cell population that has not fully differentiated.

Immature DCs are the ideal population to prime regulatory T cells as they are deficient in co-stimulatory moleucles, and priming with antigen-iDC complees might even be able to downregulated preexisting antigen specific immune responses.

Induction of Antigen specific CD8T-IL-10 producing cells: Injection of iDCs into human subjects reportedly results in inhibition of MP-specific CD8+ T cell effector function in freshly isolated T cells. Before immunization, MP-specific IFNy producing T cells were detectable in both human subjects as expected because most adults have been exposed to the influenza virus. However, after DC immunization, there was a decline in MP specific IFNy producing cells. Moreover, this decline was associated with IL10 but not IL4 producing T cells. These postimmunization IL-10 producers were CD8+CD4- cells.

Reversal of Anergic state with Antigen-processing mature DCs: 

CD25+CD4+ T cells can be expanded both in vitro and in vivo with antigen-loaded BM DCs from Balb/c mice.

CD4+CD25+ T cells proliferation vigorously to stimulation with anti-CD3 in the presence of mature bone marrow-derived DC (BMDC).

A number of studies have shown that CD4+CD25+ T cells from TCR transgenic mice will proliferate following transfer in vivo when stimulated with their cognate Ag presented by DC.

CD25-mediated suppression of T cell proliferation is also abrogated when BMDC are used as APC.

Treg anergy is dependent on TLR activaiton of BMDCs and involves the potentiation of Treg responsiveness to IL-2 by cooperative effects of IL-6 and IL-1, both of which are produced by TLR activated mature DCs.

Reversal of suppressive function with Mature DCs:

The suppressive function of Tregs is readily reversed by the maturation of DCs induced by GM-CSF and does not require TLR activation of either DCs or Tregs. Thus BMDCs derived by short-term culture (day 5-6) were permissive for suppression by CD25+CD4+ T regs, whereas BMDCs derived by long term culture (day 10-11) were not. Activation of day 10-11 BMDCs by a TLR ligand (LPS), however, does further enhance T cell proliferation.

Using splenic DCs, Il-6 was required to block the suppressive activity of Tregs. However, IL-6 was not required when using BMDCs.

Therapies Using iDCs

One possible therapy application relates to the use of iDCs to generate antigen specific regulatory CD8+T cells in vitro, which may then be used for adoptive immunotherapy in vivo. In this system, T cells are co-cultured with immature DCs in vitro at a DC to T cell ratio of about 1:10-100 and the resulting T cells are then injected for the purpose of suppressing an active immune responde.

Model of Tolerance

In one proposed model, the maintenance of self tolerance is dependent on the ratio of T4 cells to potentially pathogenic autoreactive T cells that respond to a given periopheral antigen. In a given lymph node this ratio fluctuates depending on the infectious status of the local tissue. In the steady-state, immature DCs may traffic through peripherotic debris arising form normal cell turnover in the tissue without becoming activated. Evein in the absence of inflammation, a few of these iDCs will migrate to the draining lymph nodes where they will present a panel of self peptides to both TR cells and Tpath cells. However, autoimmunity will not occur, perhaps because the autoreactive T cells are insufficiently activated by iDCs or, alternatively, because the iDC preferentially stimulate TR cells. Consistent with the latter hypothesis, TR cells can respond to much lower concnetrations of cognate peptide ligands than conventional naive CD4+T cells and iDCs express relatively low amounts of MHC class II and costimulatory molecules. Check effects of EGCG treated DCs In contrast, the presence of an infectious agent will induce DC activation and migration so that high numbers of mature DCs will arrive in the lymph node and present peptides derived from the pathogen and from self antigen. This stimulus may be potent enough to transiently override TR cell activity, permitting an expansion of anti-pathogen T cells but also allowing expansion of T path cells. This transient loss of TR cell activity will also be associated with proliferation of the TR cells themselves, analygous to the in vitro hyperstimulation of CD4+CD25+TR cells with anti-CD3 + IL-2 of anti-CD28, which results in proliferation of the TR ceels accompanied by a transient loss of suppressive activity.

See also Drugs/agents which inhibit DC maturation

DC are derived form bone-marrow progenitors (CD34+) and are present at two stages in the body. DC differentiation involves the change from multipotential hematopoietic progenitor cells (HPCs) to immature DCs (iDCs). Immature DC are present in most tissues and have the role of sentinel. Immature DC have a high capacity to capture antigens and transport them from peripheral tissues to the secondary lymphoid organs. Thus iDCs have a big capacity for Ag-uptake but a relatively poor ability to activate T cells. This differentiation is induced in vitro by exogenous cytokines such as GM-CSF and TNF-alpha for CD34+ HPCs, GM-CSF and IL-4 for monocytes, CD40 receptor cross-linking for CD34+ HPCs, or calcium ionophore alone for monocytes.

The next stage involves maturation of iDCs to mature DCs (mDCs), which exhibit enhanced Ag-presentation, up-regulated surface major histocompatibility comnplex (MHC) molecules, as well as co-stimulatory and adhesion molecules. Mature DC are present in secondary lymphoid organs and present antigens to T cells. Antigen presentation by DC to T cells occurs in the context of cell surface MHC class II molecules and co-stimulation signals, and to become fully potent APC, DC must thus undergo maturation.

After internalization, most exogenous antigens are processed through an endosomal and lysosomal pathway in which proteins are cleaved into peptides and loaded onto MHC class II molecules. Alternatively, exogenous antigens can be released into the cytosol, gaining access the the proteasome, the main non-lysosomal protease, that generates peptides and transfers them to the endoplasmic reticulum, where they are loaded onto MHC class I molecules. This exogenous MHC class I presentation is also refered to as “cross-presentation”.

What Drives DCs to Mature

In vivo, maturation (second stage) is probably triggered by “danger signals” which may include  a variety of stimuli including live bacteria and components (lipopolysaccharide (LPS), DNA), viral infection and inflammatory cytokines.

DC differentiation is plastic. Different cytokine microenvironments, which can relate to tissue localization or to prior interaction with microorganisms, induce DCs to differentiate towards different states that can polarize T cells towards different functions. Studies have shown that immature DCs mature in the following ways:

  • Microbial signaling through toll-like receptors (TLRs) is an effective way to mature DCs to their immunogenic state. Immature DCs can be considered as immunological sensors that analyze the nature of the microorganisms and other danger signals through cross-linking of their pattern recognition receptors (PRR). The majority of the known PRR recognize bacterial pathogen associated molecular patter (PAMP), such as Toll-like receptor (TLR) 2 for peptidoglycan, TLR4 for lipopolysaccharide, TLR5 for flagellin or TLR9 for CpG.
  • Different cytokine microenvironments, which can be related to the tissue localization or to prior interaction with microogranisms induce DCs to differentiate towards different states that can polarize T cell towards different functions. Different microbial stimuli induce different responses from the same DC population. Several soluble immunosuppressive factors on the maturation of DC form monocytes or CD34+ myeloid stem cell progenitors have been shown. Among these factors are a number of cytokines that are often produced by malignant cells such as TGF-?1, IL-6, vascular endothelial growth factor (VEGF) and IL-10.
  • NF-kB: TLR ligation results in NF-kB activation and this pathway is important in DC maturation. Translocation of the NFkB family members Rel B and p50 from cytoplasm to nucleus is required for myeloid DC maturation. Antigen-exposed myeloid DCs, in which RelB function is inhibited, lack cell surface CD40 expression and prevent priming of immunity, and suppress a previously primed imune response. DCs in which RelB nuclear translocation is inhibted through prevention of IkB phosphorylation, DCs generated from RelB deficient mice, and DCs generated from CD40 deficient mice similarly confer suppression. TLRs trigger DC maturation using a NFkB dependent pathway. Indirect activation of DCs by proinflammatory cytokines (Il-1, Il-18, TNF-alpha) and chemokines is also NFkB dependent.
  • T cell-derived signals. Activated CD4+ T-helper cells upregulate  CD40 ligand. Signaling through the CD40 receptor activates DCs.
  • Antigens with which DCs interact:
  • Recent studies in mice indicate that DCs also mature through interaction with natural killer T cells. This process is dependent on NK T-cell activation with the synthetic glycolipid antigen alpha-galacto-sylceramide, presented by CD1d molecules on the DCs.

Molecular Mechanisms of Maturation

The molecular mechanisms of DC maturation are not well understood but involve several routes such as NF-kB pathway and the p38 mitogen-activated protein kinase (MAPK) pathway. In vitro, bacteria-induced DC maturation involves (a) ERK kinase, allowing for DC survival, and (b) NF-kB, allowing for DC maturation characterized by increased expression of costimulatory and MHC-class II molecules, release of chemokines, and migration. This coordinated process leads to high T cell stimulatory capacity as well as IL-12 release, all of which result in the induction of protective immune responses.

Numerous publications have shown that all TLR agonists tested to date can lead to increased expression of CD40, CD80 and CD86 in at least one DC subset. NF-KB pathway  is a major transcription factor controlling the expression of these markers and thus it has been reasonable to assume that NF-kB activation following TLR signalling is sufficient to promote DC maturation. This has been put into question by the work of Hoshino et al., however, who showed a marked decrease in CD40 upregulation in STAT-1 -/- BM-DC treated with CpG or LPS compared to wild type DC. This result suggests that DC maturation in response to TLR ligation is, to a large extent, dependent on secondary production of cytokines such as type I interferons (IFN-I), which signal in an autocrine or paracine manner. Consistent with these results, IFN-I is a potent stimulus for DC maturation and IFN-I receptor (IFN-IR) is required for the adjuvanticity of Complete Freund’s adjuvant which contains several TLR ligands in the form of killed Mycobacteria. TLR agonists and/or IFN-I may further promote DC maturation via induction of TNF, IL-15 or other inflammatory cytokines, which also promote upregulation of B7 and CD40 expression on DC.

The loss of receptors specific for inflammatory chemokines is mediated by distinct mechanisms. Following stimulation with LPS, the loss is very rapid (up to 80% and 60% of surface CCR1 and CCR5 expression in 3 h). Thus this rapid down regulation cannot result from changes in transcription or mRNA stability. One proposal is that the rapid loss is mediated by a novel mechanisms that involves the production of chemokines by maturing DC, leading to homologous desensitization of the cognate receptors. Evidence for this mechanisms includes (1) maturing DC produce a number of chemokines that act on their own receptors, (2) receptor down regulation is prevented by brefeldin A and cycloeximide and (4) receptor levels can be reconstituted in mature DC by reculturing them in fresh medium without stimuli.

Importance of relB: On a molecular level DC maturation is guided by relB, a subunit of the NFkB transcription factor. RebB has been shown to play a major role in DC function by regulating CD40 and MHC expression. Upon stimulie exerted by TNF-alpha, LPS or virus-derived IL-1, relB translocates to the nucleus and promotes transcription of CD40, CD80/86 and MHC genes, all of which are indicators of DC activation. Blokage of this translocation can lock DCs in an immature state, as indicated by results using REelB-deficient mice. Most of the pharmaceuticals that inhibit DC maturation also interact with the relB pathway. For example, there is evidence that mycophenolate, mofetil, glucocorticoids and vitamin D3 all downregulate NFkB expression. RelB has even been suggested as a useful marker to qualify DC as Treg-inducing DCs. Evidence derives from observations showing that nuclar relB is absent in steady-state DCs located in peripheral tissues, whereas relB becomes upregulated in the nucleus in DCs residing in inflamed or lymphoid tissues.

P38 MAPK: LPS reportedly activates the p38 MAPK pathway in DC and this coincides with DC maturation. However, activation of p38, although necessary, is not sufficient to stimulate DC maturation, indicating that alternative pathways are required. See also P38 as an inhibitor of DC maturation The activation of the NF-kB pathway is a likely candidate. Activation of p38 may reusult in the modulation of chromatin structure and enhanced accessibility of NF-kB to the relevant elements in the promoters of cyotkine genes and other genes presumably involved in DC maturation.

JNK: was reportedly not to be involved in controlling DC maturation.

Changes which occur as DCs mature

Maturation of DC results in a complete reprogramming of the cell, with downregulation of endocytic activity, upregulation of MHC, adhesion and costimulatory molecules, as well as a striking switch in chemokine receptor usage. Some changes that take place on DC maturation include the following:

  • increased formation of stable MHC-peptide complexes. There is upregulation of cell surface MHC molecules, which in the case of both MHC I and II is due to increased biosynthesis, and in the case of MHC II is due to a prolongation of the half-life of MHC peptide complexes.
  • higher expression of membrane molecules: DCs express on their plasma membrane high levels of coreceptors such as CD80 (B7-1), CD86(B7-2), CD40, CD54, OX40L, 4-1BBL, etc. that bind costimulatory receptors on T-cells.  CD95 is also up-regulated on mature DC.  For example, LPS has been shown to up-regulate expression of cell-surface MHC class II (Iab), CD40, CE54, CDE80 and CD86 (Chen, 2002). DC-LAMP is also known to be up-regulated upon differentiation/maturation of DCs.
  • synthesis of cytokines that influence T cell proliferation and differentiation such as IL-12.
  • altered production of chemokines Maturing DCs entering the draiming lymph nodes will be driven into the paracortical area in response to the production of MIP-3? and/or 6Ckine by cells spread over the T cell zone. The newly arriving DCs might themselves become a source of these chemokines, allowing an amplifciation or persistence of the chemotactic signal. Because these two chemokines can attract mature DCs and naive T lymphocytes, they are likely to play a key role in helping Ag bearing DCs to encounter specific T cells. Upon encounters with T cells, which can take place not only in the wsecondary lymphoid organ but also the site of tissue injury, DCs receive additional maturation signals from CD40 ligand, RANK/TRANCE, 4-1BB and OX40 ligand molecules which induce the release of chemokines such as IL-8, factalkine, and macrophage derived chemokines that attract lymphocytes.
  • Alterned production of chemokine receptors that intensify movement of DCs into lymphatic vessels and lymphoid organs. Depending on their tissue of origin, immature DC express a variety of chemokine receptors (CR), most of which bind to inflammatory chemokines. For example, infiltration of graft tissues by immature DC allows these DC to take up and process graft Ag for presentation to naive T cells in draining secondary lymph nodes (DLN). The internalization and processing of Ag initiates DC maturation, which involves decrease of CR for the inflammatory chemokines and increase of the CR for the constitutive chemokines.
Send an Email. All fields with an * are required.